CliffBio
small molecule

VIGADRONE

VIGABATRIN

Loss of exclusivity—loss of exclusivity
CompanyAUCTA →See this company's full patent-cliff portfolio

Drug detail

Brand nameVIGADRONE
Active ingredientVIGABATRIN
Strength500MG/PACKET
Dosage formFOR SOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJune 2018
Marketing statusRX

More from AUCTA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

VIGADRONE patent cliff — loss of exclusivity — | CliffBio